Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRANK-103
- Development stage
- Preclinical
- Lead developer
- MindRank
- Modality
- Small Molecules
01
Overview
MRANK-103 (formerly MRANK-002) is a preclinical small molecule inhibitor developed by MindRank, specifically designed to target MYC-driven cancers. MYC is a well-known oncogenic transcription factor that is frequently overexpressed in various human cancers, but it has historically been considered "undruggable" due to its lack of a traditional small-molecule binding pocket. MRANK-103 aims to address this by utilizing MindRank's AI-driven drug discovery platform to identify novel binding sites or mechanisms to inhibit MYC activity. The program is currently in the discovery/optimization phase, focusing on oncology indications characterized by high MYC expression.
02
Targets
GSPT1 (G1 to S phase transition 1)
Beyond the preview
Go deeper on MRANK-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRANK-103.